Last reviewed · How we verify

APO-Dabigatran 150mg — Competitive Intelligence Brief

APO-Dabigatran 150mg (APO-Dabigatran 150mg) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline.

marketed Small molecule Live · refreshed every 30 min

Target snapshot

APO-Dabigatran 150mg (APO-Dabigatran 150mg) — Population Health Research Institute.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
APO-Dabigatran 150mg TARGET APO-Dabigatran 150mg Population Health Research Institute marketed

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). APO-Dabigatran 150mg — Competitive Intelligence Brief. https://druglandscape.com/ci/apo-dabigatran-150mg. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: